BACKGROUND: Pleural infection is a common complication of pneumonia associated with high mortality and poor clinical outcome. Treatment of pleural infection relies on the use of broad-spectrum antibiotics because reliable pathogen identification occurs infrequently. We performed a feasibility interventional clinical study assessing the safety and significance of ultrasound (US)-guided pleural biopsy culture to increase microbiological yield. In an exploratory investigation, the 16S ribosomal RNA technique was applied to assess its utility on increasing speed and accuracy vs standard microbiological diagnosis.
Pleural infection is a common complication of pneumonia with a high mortality, affecting 80,000 patients per year in the United States and United Kingdom combined, translating to 220 new cases per day. 1 Epidemiological data from Europe and the United
States suggest the incidence is increasing year on year and most of all in the elderly. [2] [3] [4] [5] Mortality of the disease is considerable at approximately 20% in the 6 months following initial presentation. 6, 7 Treatment for pleural infection requires fluid drainage and antibiotic therapy, which is initially necessarily broad spectrum until culture results become available. 1 In up to 40% of cases of pleural infection, a microbiological diagnosis cannot be made using standard (pleural fluid and blood culture) techniques, and antibiotic treatment is empirical on the basis of local knowledge and clinical judgment. 4, 5, 8 This lack of a specific microbiological diagnosis leads to nonspecific and broad antibiotic treatment, potentially risking inaccurate management and contributing to poor outcomes, including the development of resistance and complications of antibiotic therapies (eg, increasing incidence of methicillin-resistant Staphylococcus aureus 9 and Clostridium difficile 10 infections).
Lack of guidance on negative blood or pleural fluid microbiology may lead to medical treatment failure, which then often means surgical intervention is required in those fit enough to undergo such management, with all the associated risks inherent to such an approach. 1, 11 Methods demonstrated to increase the microbiological yield include the use of nucleic acid amplification techniques (targeting 16S ribosomal RNA sequence [16S rRNA]) that have been proposed to potentially increase overall microbiology sensitivity. 1, 11 Important questions regarding the disease microbiology remain unanswered, which may in part account for the lack of recent therapeutic advances. 12 Although infected pleural fluid is usually sampled in clinical practice because it is available for analysis, there is no direct evidence that microbes infecting the pleural preferentially inhabit the fluid. A recent animal study of pleural infection identified the presence of Streptococcus pneumoniae in the pleural tissue, raising questions as to whether sampling of the pleural tissue may improve diagnostics. 13 In conditions such as malignant pleural effusion and tuberculous pleuritis, it is well recognized that pleural biopsy has a much higher yield than that obtained from fluid alone. 14 It is hypothesized that, because of a rich blood supply in pleural tissue, bacteria may anchor in pleural tissue, with the minority of organisms existing in pleural fluid, but this theory has not been tested.
We hypothesized that ultrasound (US)-guided pleural biopsies would be safe and improve microbiological yield in addition to conventional methods in patients presenting with pleural infection. We aimed to assess the use of the 16S rRNA technique in combined pleural fluid and biopsy samples, using specifically designed primers for common microbes causing pleural infection.
Methods

Study Design
This was a pilot feasibility interventional study performed in two centers in the United Kingdom.
Subjects Enrolled
Study enrollment was offered to all subjects fulfilling the entry criteria at the Oxford University Hospitals NHS Foundation Trust (Oxford, UK) and Southmead Hospital (Bristol, UK). Subjects were screened during normal clinical practice and enrolled at the point of initial diagnostic pleural aspiration, which diagnosed pleural infection. Specific details about inclusion and exclusion criteria can be found in e-Appendix 1.
US Imaging
All patients underwent US assessment before intervention by two respiratory physicians of Royal College of Radiology Thoracic Ultrasound level I or II competence. 15 The size of effusion (small, one rib space; moderate, two to three rib spaces; large, $four rib spaces), echogenicity, and average number of septations per image were recorded.
Study Intervention
All patients underwent real-time US-guided pleural biopsies performed at the same procedure as chest drain insertion, using an 18-gauge Temno cutting needle with a throw of 2 cm (Temno BD). 16 The site of biopsies was determined during the US assessment by targeting the rib space with evidence of >3 cm of pleural fluid and no underlying vessels on Doppler investigation. Evidence of pleural thickening was not prerequisite for US-guided pleural biopsies. Between six and eight biopsies were performed until macroscopically satisfactory material was obtained. US-guided pleural biopsies were taken from only one site for safety and time reasons, as Advanced Ultrasound in Pleural Infection (AUDIO) study participants required urgent chest drain insertion for the infection. No other techniques or needles were tested in light of the results of a previous study published by our group. 16 The material was sent for microbiological examination in bottles with normal saline separately to the pleural fluid and blood for microbiological analysis in the local laboratory.
Alongside the study interventions, all patients had pleural fluid (inoculation of fluid in BACTEC bottles and normal microbiology sample containers) and blood culture at enrollment per standard treatment. 17 The same laboratory on each site tested blood, pleural fluid, and biopsies for all patients. Pleural fluid and biopsy samples were stored for further investigation in the exploratory phase of this study.
Study Outcomes
Primary End Point: The primary outcome was the frequency of positive microbiological results using pleural biopsy in addition to conventional microbiological culture and gram stain.
Secondary End Point:
The secondary outcome was the association of 16S rRNA assessment of pleural biopsy tissue.
DNA Extraction and Quantitative Polymerase Chain Reaction
DNA from both pleural fluid and biopsy samples was extracted using QIAamp UCP Pathogen Mini Kit (Qiagen, Cat No./ID: 50214). For the DNA extraction, either 2 mL of pleural fluid or the whole pleural biopsy tissue was used. Before DNA extraction, pleural fluid samples were centrifuged at 21,000g for 15 minutes. DNA quantity and quality was measured by NanoDrop 2000/2000c. All our samples passed the quantity and quality cutoff, which was 10 times the minimum amount of DNA per microliter needed for each reaction. Equal volumes of DNA were used for each quantitative polymerase chain reaction (qPCR) reaction. qPCR was performed using either 18 For the pathogen identification qPCR assays, aiming to increase the specificity of the technique, we chose the TaqMan qPCR method and designed primers for S. pneumoniae, S. aureus methicillin-sensitive (MSSA), and S. aureus methicillin-resistant (MRSA) (e- Table 2 ). For the detection of anaerobic bacteria, a previously published primer set (e- Table 1 ) was used that amplifies a 1,500 nucleotide sequence of the 16S-23S rRNA intergenic spacer. 19 Threshold cycle (Ct) values from triplicate qPCR reactions were used for the analysis.
Study Databases Used for Exploratory Phase
Samples from the AUDIO study were used to assess the 16S rRNA technique in pleural fluid and biopsies. Samples (pleural fluid and biopsies) taken from patients without pleural infection stored in the Oxford Radcliffe Pleural Biobank were used as negative control subjects. The development of specific primers was made on the basis of samples from a previously published study in pleural infection (Microbial Signal Transduction 2 database). 5 
Statistics
All analyses were performed using GraphPad Prism (version 7.0; GraphPad Software). Data are presented as mean AE SD or median with interquartile range as appropriate. Descriptive statistics were used to summarize patient characteristics. Student t tests were used to examine differences between groups with parametric data. MannWhitney U test and Dunn multiple comparisons were used for nonparametric data. Fisher exact test was used for categorical variables. Statistical significance was taken at the 5% level.
Study Approval
Ethical and regulatory approval for the study was obtained before recruitment commenced (UK research ethics committee reference 15/SC/0171). Ethics approval for sample analysis was obtained before the laboratory investigations (Oxford Radcliffe Biobank ethics committee reference 15/A252).
Study Registration
This study is registered with ClinicalTrials.gov as no. NCT02608814.
Results
Patients
A flowchart showing enrollment, intervention, and US findings of patients until primary analysis is presented in Figure 1 . A total of 25 participants were screened and 20 were recruited between June 2015 and December 2016 (17 patients from Oxford University Hospitals NHS Foundation Trust, and 3 from Southmead Hospital). Five patients were not recruited because of no established diagnosis of pleural infection or the presence of exclusion criteria. Twenty participants underwent imaging with thoracic US and US-guided pleural biopsies before chest drain insertion. None of the patients had treatment with fibrinolytics before study enrollment. Baseline demographics are provided in Table 1 .
Data Quality
The primary outcome measure (assessment of microbiological yield) was available in all (20/20) participants. There were no losses to follow-up, with 3-month postrecruitment data available in all participants who were alive.
Primary End Point
The addition of pleural biopsies to routine blood culture and pleural fluid significantly increased microbiological yield (Fig 2A) . Of the 20 patients recruited, all had results from blood and pleural fluid samples either at or before enrollment during the same treatment period. Blood samples were positive in 10% of cases, pleural fluid in 20%, and pleural biopsies in 45% (Fig 2) . Addition of pleural biopsies to routine (blood and pleural fluid) microbiological analysis increased the diagnostic yield by 25%. Detailed microbiological results are presented in Table 2 .
A total of 15/20 (75%) patients were established on antibiotic therapy before study recruitment. Of these patients, 1/15 (7%) blood cultures, 2/15 (13%) pleural fluid cultures, and 6/15 (40%) pleural biopsy cultures were positive. Our results suggest that in patients previously treated with antibiotics culturing of pleural biopsies samples is more likely to provide positive results compared with current standard practice (pleural fluid and blood samples).
Pathological investigation of US-guided pleural biopsies identified microbes on the pleural surface. An example is shown in Figure 2C with gram-positive cocci in the acute inflammatory exudate on the pleural surface.
Population With Positive US-guided Pleural Biopsies
To improve patient selection, the baseline characteristics of individuals with positive and negative US-guided pleural biopsy are illustrated in Table 3 . The data revealed no difference in terms of duration of antibiotics, severity of pneumonia with CURB-65 (confusion of new onset, blood urea nitrogen, respiratory rate, blood pressure, and age >65 years) score, C-reactive protein, pleural fluid lactate dehydrogenase, blood platelets, and WBC count that could improve patients' selection with a potential positive pleural biopsy.
Procedure Side Effects and Safety Data
There were no technical difficulties or adverse events in any patient, specifically including bleeding, vasovagal reaction, pain requiring intervention, or serious adverse events.
Use of 16S rRNA in Pleural Fluid and Biopsies
In the exploratory phase, we investigated the utility of molecular biology methods on increasing the sensitivity vs conventional procedures in AUDIO samples. 16S rRNA amplification in pleural infection-positive biopsies significantly differed compared with negative samples (P < .0001), mean positive samples 24.8 Ct, (95% CI, 23.74-26.68) and mean negative samples 32.1 Ct (95% CI, 30.65-31.79) (Fig 3A) . Pleural fluid DNA method exhibited greater mean qPCR cycle difference (P < .0001), mean positive samples 13.1 Ct (95% CI, 12.4-14.9), mean negative samples 34.7 Ct (95% CI, 33.8-35.7) compared with pleural biopsy DNA method (difference of 7.25 cycles) (Fig 3B) .
Development of Specific Primers for Pleural Infection:
Pleural fluid samples were used from a previously published study of pleural infection (the MIST-2 study) as a platform to design specific primers for microbes to improve diagnostics. 5 All TaqMan qPCR reactions for MSSA and MRSA, exhibited 100% specificity and chestjournal.org 100% sensitivity (total 42 samples) suggesting that qPCR-based pathogen detection is feasible in pleural infection (e- Table 3 ). By using universal primers for anaerobes (total, 39 samples), we were able to confirm the microbiological pleural fluid culture in 5/8 (62%) samples and detected positive anaerobes in 13/31 (42%) samples with negative pleural fluid culture (e- Table 3 ).
TaqMan qPCR reactions identified two positive samples for S. pneumoniae with negative pleural fluid samples. The two samples with positive reactions had positive blood cultures for S. pneumoniae, which confirms our results. No increase in the yield was detected with MSSA and MRSA in our database.
Discussion
The results of this study suggest that US-guided pleural biopsies are safe and significantly improve diagnostic microbiological yield compared with routine techniques in patients with pleural infection. Pleural biopsies had the highest diagnostic yield of all techniques assessed (45% positivity compared with 20% for pleural fluid and 10% for blood cultures). Furthermore, addition of pleural biopsies to blood and pleural fluid microbiological analysis increased the diagnostic yield by 25%; in these cases, the pleural biopsy was the only microbiologically positive sample obtained. Moreover, our results suggest that pleural biopsy samples are less likely to be negative because of prior antibiotics. The Given the safety and relative ease of learning and the increased yield of this technique, and that it can be performed in the same procedure as chest tube insertion under US guidance and using a common local anesthetic tract, we suggest that the technique is safe, meriting further evaluation as part of a wider study. It has the potential to become part of the standard of care in cases of suspected pleural infection.
The microbiology results from pleural biopsies potentially further our understanding of the pathobiology of this difficult to treat condition. The high biopsy yield may suggest that microbes are topographically more likely to be located on the parietal pleural surface (perhaps because of blood supply and better nutrition) rather than being "planktonic" within the pleural fluid, which is known to be acidic, hypoxic, and lacking in nutrition. If this theory is correct, it may help to explain the results seen with treatments that not only divide septations but have effects on biofilms in pleural infection. 5 The majority of patients (75% of study population) were on antibiotics before study recruitment, which might affected the percentage of positive pleural fluid culture that expected to be approximately 60% on the basis of previous literature.
That a high number of patients had positive pleural biopsy culture results despite previous antibiotics treatment highlights the limited antibiotics penetration and efficacy to the pleural space. Our results suggest that negative microbiology in this situation is more likely from pleural fluid and blood samples than from biopsy samples Culture of pleural biopsies appears more robust in the presence of previous antibiotics and this may again suggest features of pathogenesis (such as biofilm formation) in this disease.
The exploratory section of this study demonstrated the potential utility of the 16S rRNA technique using pleural biopsies. We have identified four primer sets for this assay with extremely high (93% and 89.5%) specificity and sensitivity for the detection of the four most common pathogens in pleural infection. Given that a 16S rRNA technique can be completed within a few chestjournal.org hours of receiving samples, the practical clinical utility of this technique should now be explored further.
Our results indicate that 16S rRNA is more sensitive in pleural fluid compared with biopsy; this could be related to contamination of tissue samples during processing. The specific primers tested in the AUDIO samples and in samples from a previous large-scale multicenter published study suggests the possibility of rapid diagnosis of the underlying cause of common causes of pleural infection with excellent results. 5 These four underlying etiologies (S. pneumoniae, anaerobes, S. aureus MSSA, and S. aureus MRSA) can be combined and provide results within two hours with excellent specificity and thus potential clinical impact for patients.
There are several limitations to this study. Because of the small sample size, it was not possible to establish specific primers for microbes that had not been previously cultured in our studies. Our results show that 16S rRNA technique can be negative in patients with pleural infection and signifies the limitation of using the technique in everyday clinical practice. Additionally, only two sites recruited for the AUDIO study with experienced respiratory physicians and radiologist in the technique.
US-guided pleural biopsies are safe in pleural infection and improve microbiological yield when combined with blood and pleural fluid samples. The results of this feasibility study highlight that among currently standard practice tests (pleural fluid and blood culture), USguided pleural biopsies are the most probable methods for identifying the underlying pathogen causing pleural infection. qPCR primer assessment of pleural fluid and biopsy appears to have excellent sensitivity and specificity. There is now a compelling need for large clinical studies using a pleural biopsy technique as an additional test in pleural infection and the exploration of qPCR use to improve diagnosis and management.
